NASDAQ:GOVX

GeoVax Labs Q4 2025 Earnings Results & Report

GeoVax Labs logo
$2.02 +0.32 (+18.48%)
Closing price 11/16/2026 04:00 PM Eastern
Extended Trading
$1.92 -0.10 (-4.70%)
As of 11/16/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

GeoVax Labs reported Q4 2025 earnings on April 15, 2026. The company reported EPS of $44.40.

Earnings Announcement Details

Quarter
Q4 2025
Report Date
Time
After Market Closes
Conference Call
7:00 AM ET

GeoVax Labs EPS Results

Actual EPS
$44.40
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

GeoVax Labs Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Earnings Documents

GeoVax Labs Q4 2025 Earnings FAQ

GeoVax Labs (NASDAQ:GOVX) reported earnings of $44.40 per share for Q4 2025. The report was announced on Wednesday, April 15, 2026.

GeoVax Labs Earnings Headlines

GeoVax Labs (GOVX) Expected to Post Earnings on Thursday
A $247 tool for $7
Bill Poulos is offering his $247 Instant Scanner for $7 in the Black Friday sale. It's one payment for a full year, with no re-bills and nothing to install. The catch? He isn't trying to profit on the scanner itself. Poulos is betting that once you see it deliver the night's list, you'll want more of his work for years.tc pixel
GeoVax Enters Into $1 Million Revolving Loan Agreement
GeoVax Enters Into $1 Million Revolving Loan Agreement
See More GeoVax Labs Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like GeoVax Labs? Sign up for Earnings360's daily newsletter to receive timely earnings updates on GeoVax Labs and other key companies, straight to your email.

About GeoVax Labs

GeoVax Labs (NASDAQ:GOVX) is a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer. The company’s research is based in part on modified vaccinia Ankara (MVA), a viral-vector platform designed to prompt immune responses, including through the presentation of virus-like particles.

Its vaccine pipeline includes GEO-CM04S1, an investigational COVID-19 vaccine being studied in clinical trials, as well as programs targeting other infectious diseases. GeoVax also develops Gedeptin, an investigational cancer therapy designed to make tumor cells more susceptible to treatment.

GeoVax is based in the United States and focuses on research and clinical development; its candidates are investigational and have not been established here as approved products.

View GeoVax Labs Profile